1785642-46-7

Upstream product

• 172822-68-3 tert-butyl (1S,4R)-2-oxa-3-aza-bicyclo[2,2,1]hept-5-ene-3-carboxylate 
• 1502766-14-4 tert-butyl-N-(5-hydroxy-3-piperidyl)carbamate 
• 501-53-1 benzyl chloroformate 
• 1187055-35-1 benzyl (3S,5R)-3-(tert-butoxycarbonylamino)-5-[tert-butyl(dimethyl)silyl]oxy-piperidine-1-carboxylate 

Downstream Products

• 1187055-41-9 benzyl (5S)-5-(tert-butoxycarbonylamino)-3,3-difluoropiperidine-1-carboxylate 
• 1187055-44-2 (S)-benzyl 3-(tert-butoxycarbonylamino)-5-ethylidenepiperidine-1-carboxylate 
• 1593969-81-3 tert-butyl N-[(3S,5S)-5-fluoropiperidin-3-yl]carbamate 

Relevant academic research and scientific papers

PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS

Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula (I) or (I') structure : or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula (I) or (I') compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Modular Access to N-Substituted cis 5-Amino-3-hydroxypiperidines

A sequence of oxidative cleavage/reductive amination/reductive cleavage enables the preparation of N-substituted cis 5-amino-3-hydroxypiperidines from a readily available bicyclic adduct. This new route provides straightforward and versatile access to drug-relevant scaffolds or fragments.

Pim kinase inhibitors and methods of their use

The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.

PIM KINASE INHIBITORS AND METHODS OF THEIR USE

The present invention relates to new compounds of Formulas (I) and (II), their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmac